February 1992
Volume 33, Issue 2
Free
Articles  |   February 1992
Boron neutron capture therapy of anterior chamber melanoma with p-boronophenylalanine.
Author Affiliations
  • S Packer
    Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York.
  • J Coderre
    Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York.
  • S Saraf
    Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York.
  • R Fairchild
    Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York.
  • J Hansrote
    Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York.
  • H Perry
    Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York.
Investigative Ophthalmology & Visual Science February 1992, Vol.33, 395-403. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S Packer, J Coderre, S Saraf, R Fairchild, J Hansrote, H Perry; Boron neutron capture therapy of anterior chamber melanoma with p-boronophenylalanine.. Invest. Ophthalmol. Vis. Sci. 1992;33(2):395-403.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Boron neutron capture therapy (BNCT) is a form of radiation therapy that requires selective uptake of boron by the tumor and irradiation with thermal neutrons. Phenylalanine is an amino acid precursor of melanin and when boronated (p-boronophenylalanine [BPA]) was found to be selectively taken up by Greene melanoma cells in the anterior chamber of rabbits. This tumor model was irradiated 24 hr after oral administration of BPA and was used for biodistribution studies that compared BPA and sodium pentaborate. Three groups were irradiated: group 1 (11 rabbits) received BPA followed by thermal neutron irradiation, group 2 (9 rabbits) received thermal neutron irradiation only, and group 3 (9 rabbits) served as unirradiated, undrugged control animals. Eight of the 11 tumors in group 1 were treated successfully; all tumors in groups 2 and 3 grew. Histopathologic examination did not reveal vascular or retina damage in group 1. These preliminary experiments confirm that newer boronated compounds, such as BPA, used in BNCT and improved neutron beams can provide selective irradiation of ocular melanomas.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×